Encompass Health shares are trading higher after Barclays maintained an Overweight rating on the stock and raised its price target from $95 to $101.
Portfolio Pulse from Benzinga Newsdesk
Encompass Health's stock price increased following Barclays' decision to maintain an Overweight rating and raise its price target from $95 to $101.
March 28, 2024 | 3:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintained an Overweight rating on Encompass Health and increased the price target from $95 to $101, leading to a rise in the stock price.
The positive outlook from a reputable financial institution like Barclays, especially the increase in price target, typically instills confidence among investors, leading to a short-term increase in stock price. The Overweight rating suggests that Barclays views EHC as a good investment compared to other stocks in the sector, further encouraging investment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100